Pharmacoepidemiology and pharmacovigilance
I am a postdoctoral epidemiologist in Seena Fazel’s Forensic Psychiatry research group, and I am doing research on psychiatric pharmacoepidemiology and pharmacovigilance.
I am involved in a project which aims to establish how commonly used prescription medicines are associated with risk of adverse behavioural and mental health outcomes, such as aggression (interpersonal violence), self-harm (suicides and intentional injury), unintentional injuries and accidental poisonings, hospital admissions due to mental health problems, all-cause hospitalisations, and all-cause mortality in the general population and among those diagnosed with severe mental illness.
We are using large longitudinal population-based datasets from Finland (University of Helsinki) and Sweden (Karolinska Institutet) with linked routine data to model temporal associations of episodes of prescription medicine use and risk of various adverse outcomes. This research will inform drug safety and the prevention and risk modification of suicide and interpersonal violence.
In addition to testing previously identified drug safety signals at population level, we aim to identify novel safety signals and explore potential drug repurposing/repositioning opportunities. For these objectives, we are using data sources such as pharmacovigilance databases and patient data repositories.
In particular, I am interested in the safety and repositioning opportunities of medicines used to treat asthma, allergies, autoimmune diseases, pain, and inflammation. I am also interested in the potential bidirectional pathway between immune system and mental health.